ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 6, 2015, Pages 929-937

  Minaei, Ashley Arezou ^a   Kowdley, Kris V ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ABT 267 (ombitasvir); ABT 333 (dasabuvir); ABT 450 r (paritapravir); Hepatitis C virus; Ritonavir

Indexed keywords

DASABUVIR; OMBITASVIR; PARITAPREVIR; RITONAVIR; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL EFFECTIVENESS; DRUG SAFETY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; TIME; TREATMENT OUTCOME;

ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; RITONAVIR; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; URACIL;

EID: 84925867846     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1024653     Document Type: Article

References (45)

1. Gower E, Estes C C, Hindman S, et al.Global epidemiology and genotype distribution of the hepatitis C virus.J Hepatol 2014; 61(1 Suppl): S45-57
2. Gravitz L.Introduction: a Smouldering Public-Health Crisis.Nature 2011; 474(7350): S2-4
3. Kabiri M, Jazwinski AB, Roberts MS, et al.The changing burden of hepatitis C virus infection in the United States: model-based predictions.Ann Intern Med 2014; 161(3): 170-80
4. Alter MJ, Margolis HS, Bell BP, et al.Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease.MMWR Morb Mortal Wkly Rep 1998; 47(1): 1-39
5. Davis GL, Alter MJ, El-Serag H, et al.Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.Gastroenterology 2010; 138(2): 513-21; e6
6. Razavi H, Waked I, Sarrazin C, et al.The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.J Viral Hepat 2014; 21(s1): 34-59
7. Deuffic-Burban S, Deltenre P, Buti M, et al.Predicted effects of treatment for HCV infection vary among European countries.Gastroenterology 2012; 143(4): 974-85; e14
8. Sypsa V, Touloumi G, Tassopoulos N, et al.Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection.J Viral Hepat 2004; 11(4): 366-74
9. Carney K, Dhalla S, Aytaman A, et al.Association of tattooing and hepatitis C virus infection: A multicenter casecontrol study.Hepatology 2013; 57(6): 2117-23
10. Vermehren J, Sarrazin C.New HCV therapies on the horizon.Clin Microbiol Infect 2011; 17(2): 122-34
11. Wedemeyer H, Duberg A, Buti M, et al.Strategies to manage hepatitis C virus (HCV) disease burden.J Viral Hepat 2014; 21(s1): 60-89
12. Martin NK, Hickman M, Hutchinson SJ, et al.Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.Clin Infect Dis 2013; 57(Suppl 2): S39-45
13. Burman BE, Kwo PY, Kowdley KV.Comparison of first-And second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity.Hepatol Int 2014; 8(3): 352-64
14. Carrion AF, Gutierrez J, Martin P.New antiviral agents for the treatment of hepatitis C: ABT-450.Expert Opin Pharmacother 2014; 15(5): 711-16
15. Gallay PA, Lin K.Profile of alisporivir and its potential in the treatment of hepatitis C.Drug Des Devel Ther 2013; 7: 105
16. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky J.Antiviral strategies in hepatitis C virus infection.J Hepatol 2012; 56: S88-S100
17. Stedman CA.Current prospects for interferon-free treatment of hepatitis C in 2012.J Gastroenterol Hepatol 2013; 28(1): 38-45
18. Shah N, Pierce T, Kowdley KV.Review of direct-Acting antiviral agents for the treatment of chronic hepatitis C.Expert Opin Investig Drugs 2013; 22(9): 1107-21
19. Gentile I, Coppola N, Buonomo AR, et al.Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.Expert Opin Investig Drugs 2014; 23(9): 1211-23
20. Gentile I, Buonomo AR, Zappulo E, Borgia G.Interferon-free therapies for chronic hepatitis C: Toward a hepatitis C virus-free world?.Expert Rev Anti Infect Ther 2014; 12(7): 763-73
21. Lange CM, Zeuzem S.Perspectives and challenges of interferon-free therapy for chronic hepatitis C.J Hepatol 2013; 58(3): 583-92
22. Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A.Emerging treatments for hepatitis C.Expert Opin Emerg Drugs 2013; 18(4): 461-75
23. Viekira-pak viekira-pak - viekirapak pi.pdf.2015.Available from: http://www.rxabbvie.com/pdf/viekirapak pi.pdf [Accessed 22 February
24. ProductFactsheet ViekiraPakUS.pdf.2015.Available from: http://www.abbvie.com/content/dam/abbviecorp/us/desktop/.contentrooms/downloads/.ProductFactsheet ViekiraPakUS.pdf [Accessed 22 February
25. Menon R, Klein C, Lawal A, et al.Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir.Glob Antivir J 2009; 5: 31-1
26. Bernstein B, Menon R, Klein C, et al.Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers.HepDART Kohala Coast; Hawaii: 2009
27. Lawitz E, Gaultier I, Poordad F, et al.4-week virologic response and safety of ABT-450 given with low-dose ritonavir (ABT-450/r) in combination with pegylated interferon alpha-2a and ribavirin (SOC) after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatment-naive subjects.2010; 52(4): 878A-9A
28. Lawitz E, Gaultier I, Poordad F, et al.Initial antiviral activity of the HCV NS3 protease inhibitor ABT-450 when given with low dose ritonavir as 3-day monotherapy: preliminary results of study M11-602 IN genotype-1 (GT1) HCVinfected treatment-NAiVE subjects.2010; 52(4): 1202A-A
29. Gentile I, Borgia F, Riccardo Buonomo A, et al.ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.Curr Med Chem 2014; 21(28): 3261-70
30. Asselah T.ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection.J Hepatol 2013; 59(4): 885-8
31. Ferenci P, Bernstein D, Lalezari J, et al.ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.N Engl J Med 2014; 370(21): 1983-92
32. Poordad F, Hezode C, Trinh R, et al.ABT-450/r-Ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.N Engl J Med 2014; 370(21): 1973-82
33. Clark VC, Peter JA, Nelson DR.New therapeutic strategies in HCV: secondgeneration protease inhibitors.Liver Int 2013; 33(s1): 80-4
34. DeGoey DA, Randolph JT, Liu D, et al.Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.J Med Chem 2014; 57(5): 2047-57
35. Gentile I, Buonomo AR, Borgia G.Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.Expert Rev Anti Infect Ther 2014; 12(9): 1033-43
36. Lok AS.New all-oral HCV therapies for genotype 1: a final good-bye to interferon.Clinical Liver Disease 2014; 3(6): 137-40
37. Feld JJ, Kowdley KV, Coakley E, et al.Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.N Engl J Med 2014; 370(17): 1594-603
38. Zeuzem S, Jacobson IM, Baykal T, et al.Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.N Engl J Med 2014; 370(17): 1604-14
39. Martel-Laferriere V.ABT-450/rombitasvir and dasabuvir with ribavirin eliminates viraemia in most patients with HCV infection with cirrhosis.Evid Based Med 2015; 20(1): 6
40. Gentile I, Buonomo AR, Borgia G.Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection.Rev Recent Clin Trials 2014; 9(2): 115-23
41. Ombitasvir-paritaprevir-ritonavir and dasabuvir (viekira pak).Hepatitis C Online Web site.Available from: http://www.hepatitisc.uw.edu/pdf/page/treatment/.drugs/3d Published Dec 29, 2014.Updated 2014 [Accessed 16 January
42. Kowdley KV, Lawitz E, Poordad F, et al.Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.N Engl J Med 2014; 370(3): 222-32
43. Kowdley KV, Lawitz E, Poordad F, et al.Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.N Engl J Med 2014.370(3): 222-32.Available from: http://dx.doi.org/10.1056/.NEJMoa1306227
44. Poordad F, Lawitz E, Kowdley KV, et al.Exploratory study of oral combination antiviral therapy for hepatitis C.N Engl J Med 2013; 368(1): 45-53
45. Andreone P, Colombo MG, Enejosa JV, et al.ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.Gastroenterology 2014; 147(2): 359-65.e1